Suppr超能文献

免疫球蛋白游离轻链单体-二聚体模式有助于区分恶性和前恶性单克隆丙种球蛋白病:一项初步研究。

Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.

机构信息

Laboratory of FMF and Amyloidosis, Heller Institute of Medical Research, Sheba Medical Center, Tel Hashomer, Israel.

出版信息

Am J Hematol. 2014 Sep;89(9):882-8. doi: 10.1002/ajh.23773. Epub 2014 Jun 27.

Abstract

Multiple myeloma (MM) and AL amyloidosis (AL) are two malignant forms of monoclonal gammopathies. For the purposes of prognosis and treatment, it is important to distinguish these diseases from the premalignant forms of monoclonal gammopathies, such as monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM). Routine serum/urine tests for monoclonal protein are insufficient for differential diagnosis. Thus, invasive procedures, such as tissue aspiration or biopsy, are applied. In this study, we aimed at characterization of serum-free light chain (FLC) monomer-dimer patterns to distinguish the malignant from the premalignant forms of monoclonal gammopathies. A quantitative Western blotting was applied to estimate the FLC monomer and dimer levels in AL, MM, MGUS, and SMM patients, and in control subjects (healthy individuals and patients with AA amyloidosis). AL and MM patients displayed an abnormally increased dimerization of monoclonal FLC, accompanied by higher clonality values of FLC dimers, as compared to that of monomers. These abnormalities of FLC patterns were not observed in patients with MGUS, SMM, AA amyloidosis, and healthy individuals. Analysis of FLC patterns helped to differentiate AL and MM from MGUS and SMM, a goal difficult to achieve using routine serum tests. Also, our technique might serve as a complimentary diagnostic tool in the cases with suspected AL amyloidosis, where the diagnosis of MM is excluded, while the results of amyloid typing by routine immunohistochemical techniques are inconclusive.

摘要

多发性骨髓瘤(MM)和 AL 淀粉样变性(AL)是两种恶性单克隆丙种球蛋白病。为了预后和治疗的目的,重要的是将这些疾病与单克隆丙种球蛋白病的前恶性形式区分开来,如意义未明的单克隆丙种球蛋白病(MGUS)和冒烟型骨髓瘤(SMM)。用于单克隆蛋白的常规血清/尿液检测不足以进行鉴别诊断。因此,需要进行侵袭性操作,如组织抽吸或活检。在这项研究中,我们旨在描述血清游离轻链(FLC)单体-二聚体模式,以区分恶性和前恶性单克隆丙种球蛋白病。应用定量 Western 印迹法估计 AL、MM、MGUS 和 SMM 患者以及对照(健康个体和 AA 淀粉样变性患者)的 FLC 单体和二聚体水平。与单体相比,AL 和 MM 患者的单克隆 FLC 二聚化异常增加,并且 FLC 二聚体的克隆性值更高。在 MGUS、SMM、AA 淀粉样变性和健康个体中未观察到 FLC 模式的这些异常。FLC 模式分析有助于将 AL 和 MM 与 MGUS 和 SMM 区分开来,这是使用常规血清检测难以实现的目标。此外,我们的技术可能作为疑似 AL 淀粉样变性的辅助诊断工具,在排除 MM 诊断且常规免疫组织化学技术的淀粉样蛋白分型结果不确定的情况下,该技术可能有助于诊断。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验